Zobrazeno 81 - 90
of 2 975
pro vyhledávání: ''
Autor:
Keiichiro Ishibashi, Masahito Kotaka, Toru Aoyama, Yasushi Tsuji, Naoki Nagata, Hironaga Satake, Junichi Sakamoto, Masato Nakamura, Koji Oba, Masato Kataoka, Hideyuki Mishima
Publikováno v:
Cancer Chemotherapy and Pharmacology
Background The aim of this study was to evaluate the efficacy and safety of first-line chemotherapy with re-introduction of oxaliplatin (OX) more than 6 months after adjuvant chemotherapy including OX. Methods Stage II/III colon cancer patients with
Autor:
Ririno Honma, Naoya Sakamoto, Shoichi Ukai, Hideki Ohdan, Kazuhito Naka, Daiki Taniyama, Wataru Shimizu, Kenji Harada, Wataru Yasui, Yuji Takakura, Takao Hinoi, Ryota Maruyama
Publikováno v:
Cancer Science
5‐Fluorouracil (5‐FU) is one of the most frequently used pharmacological agents in the treatment of colorectal cancer (CRC). Resistance to chemotherapy is a major cause of treatment failure of CRC, and it is a well known fact that cancer stem cel
Publikováno v:
International Journal of Oncology
Primary central nervous system lymphoma (PCNSL) is a rare subtype of extranodal non‑Hodgkin lymphoma that is unique and different from systemic diffuse large B‑cell lymphomas. The median age at diagnosis of PCNSL is 65 years and its incidence is
Autor:
Zahra Mahmoudjafari, Al-Ola Abdallah, Cassie Remker, Monia Sigle, Ghulam Rehman Mohyuddin, Joseph P. McGuirk, Emily Coggins, Siddhartha Ganguly, Leyla Shune
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e220-e226
Background Aggressive relapsed/refractory multiple myeloma (RRMM) often requires salvage cytotoxic chemotherapy. We evaluated the efficacy and toxicity of VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) with a
Autor:
Bella Pajares, Sofia Ruiz-Medina, Enrique Saez, Antonia Márquez, Laura Galvez, Begoña Jimenez, Ana Godoy, Pablo Rodriguez-Brazzarola, Maria E. Dominguez-Recio, Francisco Carabantes, Alfonso Sánchez-Muñoz, María José Bermejo, Irene López, José M. Jerez, Tamara Diaz-Redondo, Ester Villar, Héctor Mesa, Leo Franco, Nuria Ribelles, Emilio Alba
Publikováno v:
European Journal of Cancer. 144:224-231
Background CDK4/6 inhibitors plus endocrine therapies are the current standard of care in the first-line treatment of HR+/HER2-negative metastatic breast cancer, but there are no well-established clinical or molecular predictive factors for patient r
Autor:
Thamir Mahgoub, Kenneth J. O'Byrne, John Crown, Clare Hughes, Frankie A. Holmes, Virginia Espina, Anthony Davies, Marion Le Gal, Alex J Eustace, Lance A. Liotta, Kathy Gately, Norma O'Donovan, Darran P. O'Connor, Max Hasmann, Denis M. Collins, Sinead Toomey, Dalal Alsultan, Jo Ballot, Birgit Bossenmaier, N. Gaynor, Stephen F. Madden, Bryan T. Hennessy, William M. Gallagher
Publikováno v:
Clin Cancer Res
Purpose: Antibody-dependent cell-mediated cytotoxicity (ADCC) is one mechanism of action of the monoclonal antibody (mAb) therapies trastuzumab and pertuzumab. Tyrosine kinase inhibitors (TKIs), like lapatinib, may have added therapeutic value in com
Autor:
David S. Hong, Yibing Yan, Heinz-Josef Lenz, Chloe E. Atreya, Scott Kopetz, Christopher H. Lieu, Philip A. Philip, Ganiraju C. Manyam, Richard B. Lanman, Katherine A. Guthrie, Anthony M. Magliocco, Luis A. Diaz, Dipen M. Maru, Shannon McDonough, Stephen E. Wang, Kanwal Pratap Singh Raghav, Howard S. Hochster, Carmen J. Allegra, Alexey V. Sorokin, Van K. Morris
Publikováno v:
J Clin Oncol
PURPOSE BRAF V600E mutations are rarely associated with objective responses to the BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC). Blockade of BRAF V600E by vemurafenib causes feedback upregulation of EGFR, whose signa
Autor:
Tom Wei-Wu Chen, Herbert H. Loong, Sze Huey Tan, Alex K.C. Leung, Richard Quek, Chih Chi Chang, Angela Pang, Myo Myint Maw, Takeshi Hirose, Makoto Endo, Akira Kawai, Mark E. Puhaindran, Virote Sriuranpong, Siyamol Mingmalairak, Mohamad Farid, Jeffrey C.H. Chan, Wei Lin Goh, Roger K.C. Ngan
Publikováno v:
Cancer Science
Angiosarcoma (AS) is a rare disease with a dismal prognosis. The treatment landscape and prognostic factors for advanced AS, including locally advanced, unresectable, and metastatic disease remain elusive. The Asian Sarcoma Consortium is an internati
Autor:
Dongmei Zou, Yan Zhang, Jingjing Yin, Meifen Zhang, Wei Wang, Xiao Zhang, Wei Zhang, Li Zhang, Daobin Zhou
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Cancer
BMC Cancer
Backgroud Establishing diagnostic and prognostic biomarkers of primary central nervous system lymphoma (PCNSL) is a challenge. This study evaluated the value of dynamic interleukin (IL)-10 cerebrospinal fluid (CSF) concentrations for prognosis and re
Autor:
Jie Xiang, Jian Li, Chengqiang Li, Yuyan Zheng, Shengguang Zhao, Hecheng Li, Kai Chen, Yichao Han, Zenghui Cheng, Yuquan Wu, Xiaoyan Chen, Toni Lerut, Xi-Jia Feng, Weixiang Qi
Publikováno v:
European Journal of Cancer. 144:232-241
Background To investigate the safety and activity of preoperative pembrolizumab combined with chemoradiotherapy for resectable oesophageal squamous cell carcinoma (ESCC) ( ClinicalTrials.gov number, NCT03792347). Methods Twenty resectable ESCC patien